MK-677 is the only oral compound in this library that produces effects comparable to growth hormone injections. That alone is enough to make it interesting. The reasons it never got commercialized as a real drug, and the tradeoffs of using it anyway, are worth understanding before you order any.
What it actually is
MK-677, also called Ibutamoren, is a ghrelin receptor agonist. It was developed by Merck in the 1990s, originally as a treatment for sarcopenia, the muscle wasting that comes with aging. It went through clinical trials, the trials produced a complicated picture, and Merck eventually walked away from commercialization for reasons that had as much to do with regulatory strategy as with the drug itself.
How it works
Ghrelin is the hormone your stomach releases when it is empty, the one that tells your brain you are hungry. One of the things ghrelin also does, almost as a side gig, is bind a receptor on pituitary cells called GHSR1a and trigger a pulse of growth hormone release. MK-677 mimics ghrelin at this receptor.
The result is that the pituitary releases growth hormone in pulses, the way it would release it naturally in response to a meal or to exercise. This is different from injecting exogenous growth hormone, which floods the system at a steady level and tends to suppress the body's own production. With MK-677, the natural pulsatile pattern is preserved, which has theoretical advantages for the way IGF-1 (the downstream effector) gets used by tissues.
The downstream IGF-1 increase is what produces most of the visible effects: lean mass gain, improved sleep architecture, better skin and hair quality, faster recovery from training.
What the trials show
The most cited study is a two-year randomized trial in older adults, published in Annals of Internal Medicine in 2008. 65 elderly participants received 25mg MK-677 daily or placebo. IGF-1 levels in the treatment arm increased by about 33 percent. Lean mass went up by an average of 1.5 kilograms, mostly in the first year. Body composition shifted favorably. Sleep architecture moved toward younger profiles, with significant increases in deep sleep and REM.
In healthy younger adults, the data is less formal but the effect pattern is similar. Lean mass gains of 1 to 2 kilograms over a few months. Substantial improvements in deep sleep, often noticed within the first week. Skin elasticity and hair quality changes that build over months. Recovery from training enhanced enough that users frequently report being able to add training volume.
Side effects you should know about
Hunger. The amount of hunger MK-677 produces surprises everyone in the first week. It is a ghrelin agonist, after all. If you are bulking, this is a feature. If you are cutting, this is the deal-breaker that ends the experiment.
Water retention is the second universal complaint. Many users gain 3 to 5 pounds of water weight in the first month, which can mask body composition gains. The puffiness is real and visible, particularly in the face.
Insulin sensitivity drops. Fasting glucose rises modestly, sometimes 10 to 20 mg/dL. HbA1c can creep up. The effect is reversible after discontinuation, but it is real, and anyone with metabolic syndrome or pre-diabetes should think hard about it. Joint aches show up in a subset of users, similar to what HGH causes. A small fraction of users report lethargy or dampened mood.
The CHF concern
One trial in elderly hip fracture patients showed an increased rate of congestive heart failure events in the MK-677 arm versus placebo. The signal was small and the population was already high-risk, but it has shaped how cautious physicians think about long-term use. In healthy adults under 50, this risk has not been demonstrated, but it has not been ruled out either, because the trials in healthy younger populations are too short to detect it.
Dosing
10 to 25mg orally, usually in the evening because the sleep benefit is one of the more reliable effects and you might as well capture it overnight. Cycles vary. Some users run continuously for months. Others cycle eight weeks on, four weeks off, on the theory that this prevents receptor downregulation, though the evidence for this practice is thin.
Status
Not approved by the FDA. The drug went through clinical trials and was abandoned, not because it did not work but because the regulatory path for sarcopenia was not commercially attractive. It exists in a research-chemical grey market, which means quality varies wildly by source. Lab-tested third-party verification is the only way to know what you are putting in your body.
The honest closing
MK-677 does what it says on the label. It raises growth hormone. Whether you should take it depends on what you are optimizing for and how much risk you are willing to absorb on incomplete long-term safety data. For a bulking athlete in their twenties or thirties with no metabolic risk factors, the tradeoffs are reasonable. For someone with prediabetes or a family history of heart failure, the math gets uglier.
See it on you
PepScan shows what the kind of lean mass and recomposition MK-677 produces could look like on your specific frame. Snap one photo and you get a photoreal projection. The hunger, water, and insulin tradeoffs are real, but you cannot weigh them properly without seeing what you are weighing them against.